Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Plasma therapy is used for treatment of many disorders such as hair loss, tendon injuries, acute injuries, post-surgical repair, and osteoarthritis and currently for treatment of COVID–19. Several manufacturers are initiating plasma processing in order to tackle the spread of the coronavirus across the world. Therefore, the global plasma therapy market is expected to witness significant growth during the forecast period.

Global Plasma Therapy Market - Impact of the Coronavirus (COVID – 19) Pandemic

On 24th August 2020, the Food and Drug Administration (U.S. FDA) approved the Convalescent plasma therapy for treatment of Covid – 19 patients in the U.S., without completing the clinical trial due to the exponential increase in the coronavirus infected patients. Convalescent plasma therapy uses blood from people who've recovered from the coronavirus infection to help others recover. On 3rd June 2020, researchers from the Houston Methodist Hospital in the U.S. initiated clinical trials for recording efficacy of the plasma therapy when plasma is transfused from recovered Covid-19 patients into critically ill patients. According to the researchers, 19 out of 25 patients were showing signs of recovery post plasma therapy and 11 patients were later discharged from the hospital following recovery.

Furthermore, many organizations are involved in increasing awareness about donation of plasma. Therefore, the global plasma therapy market is expected to witness growth due to the lack of an appropriate proper vaccine or drug for the treatment of Covid – 19 patients.

The global plasma therapy market is estimated to be valued at US$ 226.13 million in 2020 and is expected to exhibit a CAGR of 14.1% during the forecast period (2020-2027).

Figure 1: Global Plasma Therapy Market Share (%) Analysis, By Type 2020

Plasma Therapy  | Coherent Market Insights

Companies are engaged in inorganic activities such as collaborations to develop new treatment plans for patients suffering from the coronavirus.

For instance, on 7th April 2020, Takeda and CSL Behring collaboratively developed a new treatment for patients suffering from the coronavirus infection. The treatment plan involves using blood plasma of patients who have recovered from the infection by further isolating the antibodies from the plasma and injecting it in patients. This therapy triggers an immune response in the body of the patients which can help them survive the infection. Such collaborations are expected to increase the global plasma therapy market growth during the forecast period.

Product launches are expected to drive growth of the global plasma therapy market during the forecast period.

For instance, in 2019, Adimarket, LLC, a subsidiary of the Global Stem Cells Group, launched platelet rich plasma (PRP). PRP is a new treatment option in regenerative medicine. Adimarket, LLC, will provide the PRP kit to physicians along with the treatment protocol, so that patients requiring critical aesthetic, wound and orthopedic care can receive affordable and easy treatment.

Global Plasma Therapy Market – Restraints

The absence of compensation policies as well as high cost of the plasma therapy treatment are expected to restrain the global plasma therapy market growth during the forecast period.

request-sample

Plasma Therapy Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 226.13 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 14.1 % 2027 Value Projection: US$ 573.04 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Type: Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF).
  • By Application: Infectious Diseases, Dental, Nerve Injury, Cardiac Muscle Injury, Other Applications.
  • By End-User: Hospitals & Clinics, Research Institutes, Others.
Companies covered:

Octapharma AG, China Biologic Products Holdings, Inc. Bio Products Laboratory Ltd., Kedrion S.p.A , Grifols, S.A., CSL, Biotest AG., Takeda Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA and LFB SA

Growth Drivers:
  • An increasing number of product launches
  • The increasing number of collaborations, partnerships and acquisitions
Restraints & Challenges:
  • High cost of treatment
  • Lack of reimbursement

Global Plasma Therapy Market – Regional Analysis

Companies in North America are focused on inorganic strategies such as collaborations and partnerships to increase the supply of plasma to processing centers and ensuring that a treatment option is available for rare and serious disorders. For instance, in 2017, KEDPLASMA LLC, a subsidiary of Kedrion Biopharma Inc. entered a plasma supply agreement with ImmunoTek Bio Centers, LLC, in which, the ImmunoTek Bio Centers, LLC, developed a total of 28 plasma collection centers for Kedplasma LLC in the U.S. Kedplasma will use the plasma to manufacture different plasma therapies for rare and chronic disorders. Such factors are expected to drive the plasma therapy market growth in North America.

Figure 2: Global Plasma Therapy Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

Plasma Therapy  | Coherent Market Insights

Governments in Asia–Pacific are involved in research and development of new treatments for COVID-19. For instance, on 30th June 2020, the government of Maharashtra, a state in India, launched Platina, one of the largest trials across the globe for treatment of COVID-19 patients. The project aims to provide free plasma therapy at 21 government centers in Maharashtra to increase the chances of survival of the infected patients. The government is also spreading awareness among recovered patients regarding plasma donation so that the plasma can be processed and utilized for therapy. Such projects are expected to boost the global plasma therapy market growth during the forecast period.

Global Plasma Therapy Market – Competitive Landscape

Some of the key players involved in the global plasma therapy market are Octapharma AG, China Biologic Products Holdings, Inc. Bio Products Laboratory Ltd, Kedrion S.p.A , Grifols, S.A., CSL, Biotest AG., Takeda Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA, LFB SA., and Immunotek Bio Centers

Plasma therapy is a promising treatment against coronavirus, and many rare and serious disorders. The blood which is donated by the donor is processed in a processing facility to obtain plasma. Similarly, for treatment of coronavirus infected patients, the plasma is isolated from the donor. The donor is also the patient who is recovered from the infection. The donor plasma consists of antibodies which were generated in order to fight the antigens i.e. the coronavirus. The blood from the donor is processed in processing centers which is then injected in the blood of the patients.

Market Dynamics

Regulatory authorities are interested in conducting clinical trials for development of new treatment options for coronavirus infected patients. For instance, on 18th April 2020, The Drug Controller General of India accepted the proposal of the Indian Council of Medical Research (ICMR) for conducting clinical trials of convalescent plasma in COVID-19 patients. The ICMR has submitted a list of institutes which are interested in the trial.

In convalescent plasma therapy, the antibodies are recovered from the blood of patients who have recovered from COVID-19 and are injected in the blood of injected patients. The clinical trial aims to assess the efficacy of convalescent plasma to limit complications in COVID-19 patients and to evaluate the safety of treatment with anti SARS-CoV-2 plasma in coronavirus-infected patients. The rising number of clinical trials is expected to increase treatment options for coronavirus infected patients and spur the global plasma therapy market growth during the forecast period.

Companies are receiving approvals from regulatory authorities for the setup of a new manufacturing facility. For instance, in 2019, Takeda Pharmaceutical Company Limited received approval from the U.S Food and Drug Administration (U.S FDA) for its new pharmaceutical manufacturing facility near Covington, Georgia. The facility will produce FLEXBUMIN 25% [Albumin (Human), USP, 25% Solution]. The medicine is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome, and nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of newborns. The new facility will expand the product portfolio of the company which is expected to favor the global plasma therapy market growth during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global plasma therapy market, market size (US$ 226.13 Mn), and compound annual growth rate (CAGR (14.1 %)) for the forecast period (2020-2027), considering 2019 as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global plasma therapy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies.
  • Key players covered as a part of this study are Octapharma AG, China Biologic Products Holdings, Inc. Bio Products Laboratory Ltd., Kedrion S.p.A, Grifols, S.A., CSL, Biotest AG., Takeda Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA, LFB SA, and Immunotek Bio Centers.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global plasma therapy market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for plasma therapy market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Plasma Therapy Market, By Type:
    • Pure PRP
    • Leucocyte-rich PRP
    • Pure Platelet-rich Fibrin (PRF)
    • Leukocyte-rich Fibrin (L-PRF)
  • Global Plasma Therapy Market, By Application:
    • Infectious Diseases
    • Dental
    • Nerve Injury
    • Cardiac Muscle Injury
    • Other Applications
  • Global Plasma Therapy Market, By End User:
    • Hospitals & Clinics
    • Research Institutes
    • Others
  • Global Plasma Therapy Market, By Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Infectious Diseases
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Infectious Diseases
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Treatments of Infections
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Infectious Diseases
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Infectious Diseases
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Type:
        • Pure PRP
        • Leucocyte-rich PRP
        • Pure Platelet-rich Fibrin (PRF)
        • Leukocyte-rich Fibrin (L-PRF)
      • By Application
        • Infectious Diseases
        • Dental
        • Nerve Injury
        • Cardiac Muscle Injury
        • Other Applications
      • By End-User
        • Hospitals & Clinics
        • Research Institutes
        • Others
  • Company Profiles
    • Octapharma AG
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • China Biologic Products Holdings, Inc.
    • Bio Products Laboratory Ltd.
    • Kedrion S.p.A.
    • Grifols, S.A.
    • CSL, Biotest AG.
    • Takeda Pharmaceutical Company Limited.
    • DePuy Synthes
    •  Regen Lab SA
    • LFB SA
    • Immunotek Bio Centers.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Application
      • Market Snippet, By End-User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Strategies
    • Regulatory Scenario
    • New Product Launches/Approvals
    • Porter’s Analysis
    • PEST Analysis
  4. COVID – 19 Impact Analysis
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Strategies
  5. Global Plasma Therapy Market, By Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Pure PRP
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Leucocyte-rich PRP
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Pure Platelet-rich Fibrin (PRF)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Leukocyte-rich Fibrin (L-PRF)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Plasma Therapy Market, By Application, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Infectious Diseases
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Dental
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Nerve Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cardiac Muscle Injury
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Other Applications
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Plasma Therapy Market, By End User, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals & Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Research Institutes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Plasma Therapy Market, By Region, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2027
      • Regional Trends
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
      • Middle East
        • Market Size and Forecast, By Type, 2016 – 2027, (US$ Million)
        • Market Size and Forecast, By Application, 2016 – 2027, (US$ Million)
        • Market Size and Forecast, By End-User, 2016 – 2027, (US$ Million)
        • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
          • GCC
          • Israel
          • Rest of Middle East
  9. Competitive Landscape
    • Company Profiles
      • Octapharma AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • China Biologic Products Holdings, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Bio Products Laboratory Ltd. 
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Kedrion S.p.A 
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Grifols, S.A.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • CSL
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biotest AG
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Takeda Pharmaceutical Company Limited.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • DePuy Synthes
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Regen Lab SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • LFB SA
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Immunotek Bio Centers.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 21 market data tables and 22 figures on "Global Plasma Therapy Market” - Forecast to 2027”

Frequently Asked Questions

The global plasma therapy market is expected to register a CAGR of 14.1% during the forecast period (2020-2027).
The value of the global plasma therapy market is estimated to be US$ 226.13 million in 2020.
The prominent players in the plasma therapy market are Octapharma AG, China Biologic Products Holdings, Inc. Bio Products Laboratory Ltd. , Kedrion S.p.A , Grifols, S.A., CSL, Biotest AG., Takeda Pharmaceutical Company Limited., DePuy Synthes, Regen Lab SA and LFB SA
The plasma therapy market is expected to be valued at US$ 573.04 million in 2027.
North America and Europe are the major regions in the plasma therapy market.
The increasing number of product launches and collaborations, partnerships and acquisitions by market players are expected to drive growth of the plasma therapy market.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner